Stephen M. Ansell, M.D., Ph.D.

Location

Contact

SUMMARY

Stephen M. Ansell, M.D., Ph.D., is a hematologist and oncologist who also conducts cancer research. Dr. Ansell studies the biology of B cell cancers, including Hodgkin's lymphoma, Waldenstrom macroglobulinemia and non-Hodgkin's lymphoma. Dr. Ansell also investigates the role of the tumor microenvironment in supporting cancer cell growth and survival.

Focus areas

• T cell activation and T cell exhaustion. Dr. Ansell studies why the immune response to cancer is suppressed.
• Tumor-associated macrophages and monocytes. In this research, Dr. Ansell aims to understand the role of phagocytic cells in lymphoma.
• Bone marrow microenvironment in Waldenstrom macroglobulinemia. Dr. Ansell studies the role of cytokines and immunologically active signals in activating or suppressing tumors and promoting immunoglobulin production.

Significance to patient care

Dr. Ansell's goal is to translate knowledge gained from his research into new treatment approaches. Dr. Ansell's research contributed to the use of immune checkpoint therapy in lymphomas. In addition, Dr. Ansell led the clinical trial that resulted in the approval by the U.S. Food and Drug Administration (FDA) of nivolumab (Opdivo) for Hodgkin's lymphoma.

Professional highlights

• Enterprise Deputy Director and Senior Deputy Director, Midwest, Mayo Clinic Comprehensive Cancer Center, 2022-present.
• Chair, Scientific Advisory Committee, International Waldenstrom's Macroglobulinemia Foundation, 2015-present.
• Member, Scientific Advisory Board, Lymphoma Research Foundation, 2015-present.
• Member, Scientific Committee, Leukemia & Lymphoma Society, 2015-present.
• Associate editor, American Journal of Hematology, 2011-present.
• Dorotha W. and Grant L. Sundquist Professor of Hematologic Malignancies Research, 2022.
• LLS Excellence in Scientific Service award, Leukemia & Lymphoma Society (LLS), 2022.
• Ernest Beutler Lecture and Prize award, American Society of Hematology, 2021.